A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
Latest Information Update: 14 Jan 2026
At a glance
- Drugs Diazoxide (Primary)
- Indications Prader-Willi syndrome
- Focus Registrational; Therapeutic Use
- Acronyms DESTINY PWS
- Sponsors Soleno Therapeutics
Most Recent Events
- 05 Jan 2026 According to a Soleno Therapeutics media release, data from this trial was published in the peer-reviewed Journal of Clinical Endocrinology and Metabolism (JCEM).
- 25 Jun 2025 Results presented in Soleno Therapeutics Media Release
- 25 Jun 2025 According to a Soleno Therapeutics media release, the company presented new data on VYKATTM XR , at the 2025 United in Hope: International Prader-Willi Syndrome Conference.